| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.094 | 0.004 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.093 | 0.005 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.094 | 0.005 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.006 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.006 |